Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Transplant with Retroviral Marking for CML
NCT00005986Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2000
- Primary completion
- Sep 2004
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of LN-neo transduced autologous CD34+ cells in chronic myelogenous leukemia (CML), sponsored by Masonic Cancer Center. Started Aug 2000; status: terminated.
02
Drugs
LN-neo transduced autologous CD34+ cells
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00005986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005986.